Bio News
Lifemine Therapeutics has raised $263 million (approximately 374 billion won) to develop a drug for organ transplantation. The company secured the funding through a $75 million Series D financing and a $188 million Series E financing. Lifemine plans to use the funds to conduct a phase 2 trial in kidney transplant recipients and a phase 1b trial in patients undergoing pancreatic islet cell transplantation.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
